Bioengineers based in the US have designed a “DNA-binding editorial assistant” that will allow gene-editing technology, like CRISPR, to access previously inaccessible genes of interest. The new protein design can be used to open up areas of the DNA that are obscured by chromatin, which would improve CRISPR efficiency and aid in developing more precise gene-editing techniques to combat disease.
A new study by Northwestern Medicine has become the first to compare gene expression levels in African American populations by studying the levels of mRNA expressed in the liver. Previous studies have compared only African and European individuals separately and this study aimed to address the “grey” area of mixed ethnicities.
In an exciting new development, researchers have now developed a CRISPR-Cas9 system complexed with Chemical Epigenetic Modifiers (CEMs) that allowed dose-dependent activation of gene expression.
A new biomarker that can identify depression patients experiencing a lack of motivation could be used to tailor anti-depressant drugs to patients, depending on the specific symptoms of the disease they display. Depression is one of the most common psychiatric disorders in the world and affects about 9% of the US population. However, as less […]
SAN DIEGO, October 1, 2019 — Molecular Assemblies, Inc., today announced that it has raised a $12.2 million Series A financing led by iSelect Fund and joined by existing investors, Agilent Technologies, Alexandria Venture Investments, and Keshif Ventures. The proceeds of the financing will be used to advance the company’s proprietary enzymatic DNA synthesis technology to […]
51% of child cancer patients in a recent trial had gene mutations in their tumours that could be targeted by an existing adult cancer drug. However, due to clinical obstacles only 7% were able to receive the relevant drug, raising concerns about the lack of cancer therapies available for children. Treating cancer in children is […]
A newly developed ‘electronic nose’ can measure chemicals in the breath of small cancer lung patients to determine if they will respond to immunotherapy treatment. Immunotherapy is Changing Cancer Care Immunotherapy treatments harness the body’s immune system to fight the cancer cells, which is transforming the treatment of advanced stage cancers. However, only a small […]
Scientists have developed tattoos that change colour depending on the interstitial fluid concentration of key biomarkers. The development is a step towards developing quicker diagnostics. The biomarkers studied were pH, glucose and albumin. Variation of blood pH can be indictive of a range of health conditions and glucose sensing is extremely useful for monitoring diabetes. […]
Researchers have developed a new technique to pinpoint immune cells in cancer patients that are reactive against their disease. This research could lead to more targeted immune-based therapies for cancer patients. Immunotherapy is a relatively new field of cancer treatment which works by promoting the patient’s immune system to fight against the cancer. Although immune […]
Biobank 2019 – An Interview with Anthony Whetton, Professor of Cancer Cell Biology, University of Manchester
The UK Biobank’s 2019 scientific conference concluded this month. We talked to speaker Anthony Whetton, Professor of Cancer Cell Biology at the University of Manchester and Director of the Stoller Biomarker Discovery Centre, about large-scale multi-omic data within UK Biobank.
How DNA is packaged in human fat cells could be the reason why humans became fatter than their closest primate relatives, new research has shown. Whilst the healthy range for human body fat percentage lies between 14% and 31%, other primates have body fat percentages lower than 9%. The genetic reasons behind this difference could […]
Intermountain Healthcare and deCODE Genetics, a subsidiary of Amgen based in Iceland, have announced a major joint collaboration and study of 500,000 genomes centred around discovering new connections between genetics and human diseases. The study represents the largest US DNA-mapping attempt from a single population.
BIO 2019 – An Interview with Irene Rombel, Senior Director and Head of Strategic Analysis at Janssen
With the recent conclusion of the Biotechnology Innovation Organization’s BIO 2019 event, we thought we’d talk to some of the fascinating individuals who were present to showcase their innovative ideas or technologies. Irene Rombel, Senior Director, Head of Strategic Analysis – External Innovation, Discovery, Product Development & Supply, at Janssen Research & Development, spoke at BIO 2019 about gene therapy and the next generation of biotherapeutics. We spoke to her about her thoughts on the gene therapy field, and the future for companies in that space.